Articles related to BIOLOGIC TREATMENTS

CMR-guided therapeutic approach decreased rates of recurrence, exposure to glucocorticoids, and pericardiocentesis, demonstrating measurable practice improvements.

Two biologic-naive skin of color patients achieved IGA reduction from 3 to 1 with significant BSA improvement and sustained 6-month follow-up results.

Continuous mirikizumab treatment demonstrated durable efficacy across multiple outcome measures for over three years, with 70.1% of week-52 remitters maintaining clinical remission at week 152 and comparable quality of life improvements in both biologic-naïve and biologic-failure patients.

Combined omalizumab-OIT therapy demonstrated an impressive 50-percentage-point advantage over placebo in food challenge success rates for children with multiple food allergies.

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

Understanding the role of antidrug antibodies in RA treatment can significantly impact patient management. Stay updated on how these antibodies correlate with bDMARD effectiveness to optimize your treatment plans.